Tumor-infiltrating T cells--friend or foe of neoplastic cells?

The clinical response to immunotherapy for metastatic colorectal cancer remains unsatisfactory. Dr. Giorgio Parmiani writes that one of the main drawbacks in the development of effective immunotherapy for colorectal cancer is the lack of an adequate number of molecularly defined tumor antigens that could be used in clinical studies.